This week in Drug Discovery (31 August – 4 September 2026)
News round-up for 31 August – 4 September 2026 by Megan Thomas, Content Team at DDW.
This week’s news roundup covers new developments in vaccines, drug approvals, cardiovascular therapies and cancer drug response, alongside DDW’s upcoming digital forum focused on the technologies, strategies and investment trends shaping early-stage drug discovery: Drug Discovery Innovators & Investors Digital Forum.
The top stories:
Certificate of attendance: Drug Discovery Innovators & Investors Digital Forum
With less than a month to go, the Drug Discovery Innovators & Investors (DDII) Digital Forum will bring together leaders and experts from across the drug discovery ecosystem on 30 September 2026 to explore the technologies, strategies, therapies and investment trends shaping the future of early-stage drug discovery.
GSK reveals plans to advance mRNA flu vaccine to Phase III
GSK has revealed that its mRNA seasonal influenza (flu) vaccine candidate has shown higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines.
FDA extends Mounjaro approval to include reducing cardiovascular risk
The US Food and Drug Administration (FDA) has approved Lilly’s Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE) in adults with type 2 diabetes.
Landmark safety data support therapeutic angiogenesis
Safety evidence announced at the ESC Congress 2026 by Isomab has reinforced the potential of a new class of therapies designed to promote blood vessel growth as a disease-modifying approach for coronary artery disease (CAD).
Protein build-up may shape cancer drug response, study finds
The way cancer-causing proteins accumulate in tumours may influence how effectively Proteolysis Targeting Chimeras (PROTAC) drugs can remove them, a new study suggests.
